{"name":"SURPRISE Study Group","slug":"surprise-study-group","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Tocilizumab plus methotrexate","genericName":"Tocilizumab plus methotrexate","slug":"tocilizumab-plus-methotrexate","indication":"Rheumatoid arthritis (moderate to severe, active disease)","status":"marketed"}]}],"pipeline":[{"name":"Tocilizumab plus methotrexate","genericName":"Tocilizumab plus methotrexate","slug":"tocilizumab-plus-methotrexate","phase":"marketed","mechanism":"Tocilizumab blocks IL-6 receptor signaling to reduce inflammation, while methotrexate inhibits dihydrofolate reductase to suppress immune cell proliferation.","indications":["Rheumatoid arthritis (moderate to severe, active disease)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxOazZkMXFKZHR4bGE5UmlIVVRHaXgyWUVzNUhJQzhKQ0V1TElGb09XWTlOUU9LYW81RWQ0dURvZXg0a3FMSlhXTXJ0X0dzWk9LTDh6bVlhOWxJbklBcDFUb1dsbXB3SGlXeUlGTzNjeWpoRUNJZzZ5N19WbzJUV0phVU9HQzl2STV4NVV1Mi14OTl5dDR1OXV3eTNCT2RPZw?oc=5","date":"2026-03-27","type":"trial","source":"BioPharma Dive","summary":"AstraZeneca lung drug gets ‘surprise’ win in COPD trials - BioPharma Dive","headline":"AstraZeneca lung drug gets ‘surprise’ win in COPD trials","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxNQ1hpbEZhUEM4UXFzdGVtZG5vRG0xNlR6MG1xRldKemZSdEI1d2pYMXlJRElaUTh1VXZPRy1Bb1B2MEtLNU9IRUxvV1JOSklEdkpwZzBHeVV5ZTlfajU1aU9ZMjNNNmViMzJvRUp6clFBWUZpYzRNY1RGelJaWTNfcFQ4SE8xVGcxT2FvdlRSRENkaURObDF6M3loZWZqMmozTzZiOXowbDFtTEJ1WEtPVEM0cWNYWDlMaEZNc0lnYw?oc=5","date":"2026-02-23","type":"earnings","source":"TradingView","summary":"What's in Store for These 5 Medical Companies This Earnings Season? - TradingView","headline":"What's in Store for These 5 Medical Companies This Earnings Season?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxQeGNEVUpaMWFhMG9jYy01QWFQejVkRkxNa0Z0Z182QVhfWmFuVmZLcTdnbmZvQWZkVGdrbUltZENxRWtKX0o2R19YdVZkOWkzQXlLbXZpU2NCQUtyWjdGQTZvdmw1aDZRSDVDQTlZN183dVBnWEpFaXRYb01qUmlacV9ya0R0NW5wUUgySUVFRkRDUS1oSnpUNUlGSlMyS09JVDhPaWtRUlhFZGw0bVNWeGZMcElyeWNyUTNEMTNaRXI?oc=5","date":"2026-02-17","type":"earnings","source":"TradingView","summary":"Recursion Pharmaceuticals to Report Q4 Earnings: What's in the Cards? - TradingView","headline":"Recursion Pharmaceuticals to Report Q4 Earnings: What's in the Cards?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxOM2ZqYnJsbGxWYTdLNVJlaXNzT1NrN1ZVTmVTUjZVRFVOY2Z5YWVrbm8zcnBjc0V1SlRvRUplM2ZzRDRSS2tubHVnYW94bHVGbXpPY2pOdXc2TVdPa1FHNWtZZTNpT1psd2FRa3lUUzlVR2hiVTA0cnU1R1gyeDNBOU1TVWVqZW81eksycjlwVDVrbkt1NzRYdXl3OTNrVkI5M1l2akZHUQ?oc=5","date":"2026-01-02","type":"regulatory","source":"Fierce Biotech","summary":"Sanofi, Corcept surprised by FDA rejections for MS, Cushing's syndrome drugs - Fierce Biotech","headline":"Sanofi, Corcept surprised by FDA rejections for MS, Cushing's syndrome drugs","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxNLVlKUnVDcmtCYkw1UTMzNHo5VV9FUE9CSFU1RmZaNXVScGFYN2JXbG1heDdob2pLYTVDNGRXQmZIT3k1cHNyZ3I2RHIxQl90YmlhUUR1bC1PYThySmZWdXd4cm1EMUpaSHVpa0VwVm83T2RDZ1BuWUdtNnhKVVdLQUZvS0RDa1NxbnZiVkxQQVJRNU9za3JZTnBMVks2U0pHSHJOaXNYZDlDOTNQYUNCWWh0eTZZdw?oc=5","date":"2025-12-18","type":"deal","source":"Seeking Alpha","summary":"Recursion Pharmaceuticals: Upgrading To Buy - My Most Surprising Call Of 2025 (RXRX) - Seeking Alpha","headline":"Recursion Pharmaceuticals: Upgrading To Buy - My Most Surprising Call Of 2025 (RXRX)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxNQndpWXg3UDNJNjZjYlhpcHdpZDNiemNMcTRWSnpNRG1HOXd3UFJ1SWdSUUpUS20yYXBjMTJIcnRrZ0xuY3hrSUlrUHNWZ3FNdWtpQXF0N3RIc2lid2c2NnhFSGZEMXh6M2JBMEVxU3NnRDF0ODhvM0JKYUJId05CelRMcWFtQmpmUG81WkJkZkgtUnVfeU5Md1BOMmlKM2xwXzZNRUlEU2dpczNZMUFDQTVPeU5xTjVo?oc=5","date":"2025-12-17","type":"trial","source":"Fierce Biotech","summary":"Vistagen phase 3 study sees placebo surprise, putting future of social anxiety asset into question: analyst - Fierce Biotech","headline":"Vistagen phase 3 study sees placebo surprise, putting future of social anxiety asset into question: analyst","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxPQUE1TFVrelB5dWduSVlTYWk0bjFOakxpbU9ObWtUMjhWeEJmNzAyTm8tRXV6bF9zM1BJSF9hUTdjdTdEVmNNOHl1V1NCSjhORGNCTUZjazdFaGZMSmhCb1M3Y0dZek5VV3cza2cxTWxNVS1GaTF5czFvYnJidEIxYTVtaVZRVVdrTW5wSjhqR0N4WFBwdkRyUk9fR0NZaVN6dXRRclZ4RVBrUi13dkE?oc=5","date":"2025-11-03","type":"regulatory","source":"BioPharma Dive","summary":"UniQure dives after FDA’s ‘very surprising’ reversal on Huntington’s gene therapy - BioPharma Dive","headline":"UniQure dives after FDA’s ‘very surprising’ reversal on Huntington’s gene therapy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxOQlJOMTU1VDdndFczYm9LeXRoRG4waVRGSGtLc25INFB5MUNHN1VOYU1jamZwTGlYelVjY1l6dm9QNjVmUkU1dHJ6a2pZaFA0MWNmZDZpRHR2YVp6LWFzdEJMTEI1UkdYTnlMZGRmTkxCN1l4QkdSNkpPTTVXeHgzZHpwTjNlU3cydzBaODBaSmVZbG0yUGxV?oc=5","date":"2025-09-08","type":"pipeline","source":"The People's Pharmacy","summary":"Show 1397: The Surprising Secrets of Sunlight’s Health Benefits (Archive) - The People's Pharmacy","headline":"Show 1397: The Surprising Secrets of Sunlight’s Health Benefits (Archive) - The People's Pharmacy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMib0FVX3lxTE94SjZrMVdyazM2dml5TmF6ZE0xLVNWWmZpVDBvVEpoOVdIOEVsSWxzV01oZmpwZDZvd0NNN0Q4TFlYNXBLLVFlcWRFaWl0Y1ZqeHN0Y25XTWs4SnBieGdUOWlXa1dsOGJ4TUgyblNuSQ?oc=5","date":"2025-09-07","type":"trial","source":"ScienceDaily","summary":"Common allergy spray slashes COVID-19 risk in surprising trial - ScienceDaily","headline":"Common allergy spray slashes COVID-19 risk in surprising trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE5XSWRqNVRYdTNtTVRyMXkwXzhhT0lCWHJ3eUUwdHA3RUR4VmNuVUJDazBPUldYR2hUNW9MbTlfZmlHNnJRWlVXSGQyTGUwNGVFT0Z5dk5jTWd5QnZaWEtF?oc=5","date":"2025-07-01","type":"pipeline","source":"Nature","summary":"Transparent research: can big tech learn from big pharma? - Nature","headline":"Transparent research: can big tech learn from big pharma?","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-06-04","type":"trial","source":"The Economic Times","summary":"Sun Pharma Advanced Research shares tank 20% after psoriasis drug fails Phase 2 trials - The Economic Times","headline":"Sun Pharma Advanced Research shares tank 20% after psoriasis drug fails Phase 2 trials","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxPeFRZQjR5VHhHYnBKV0xfMFpZMEhHLVZXSEtqcXJzQTNXWXlpVTE1Xy02X1BhMm0zajA1YlhpaHZFblZiQUIxNHdrVFpqN0kzUUVfc1pHZkhtTHpOZVNjRHNXTmZXZEhKSWNhbWtrUUg1REhwU1djUVA1c1g3S0FUbENqX1dpQUFZNjlwekJHR2Utdw?oc=5","date":"2025-05-23","type":"pipeline","source":"Politico","summary":"RFK Jr.’s report had a surprise target: Your doctor - Politico","headline":"RFK Jr.’s report had a surprise target: Your doctor","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}